Opinion|Videos|September 18, 2024
Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib
Medical experts compare the efficacy and safety of new therapies, including FTD/TPI plus bevacizumab and fruquintinib, to regorafenib for metastatic colorectal cancer.
Advertisement
Episodes in this series
Video content above is prompted by the following:
How do these new therapy options (FTD/TPI plus bevacizumab, fruquintinib) compare with regorafenib in terms of efficacy and safety?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
How Hospital Specialty Pharmacies Are Closing the Pharmacy Desert Gap
2
Targeting Oxidative Stress Could Fill a Gap in the Vitiligo Treatment Toolbox
3
Patients on GLP-1s Increasingly Carry Diagnoses for New Indications
4
5 FAQs: Ebola Outbreaks and the Challenge of Public Trust
5